{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:03:19Z","timestamp":1764784999703,"version":"build-2065373602"},"reference-count":24,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Borderline ovarian tumors (BOTs) are non-invasive tumors frequently diagnosed in young patients. Surgical removal of the uterus, fallopian tubes, ovaries, and omentum is considered definitive management, however fertility-sparing approach is a recognized option. Surveillance is important due to known recurrence, but there is controversy over the effectiveness of follow-up modalities. The objective is to determine the efficacy of ultrasound screening in identifying tumor recurrence. This retrospective chart review evaluated all patients consulted and\/or treated surgically at our institution from January 2015 to June 2020 diagnosed with BOT. Patients were excluded if concurrently diagnosed with another gynecologic malignancy, did not have yearly ultrasound follow-up, or were lost to follow-up. This study included 56 patients, 17 of whom underwent fertility preserving surgery. The overall rate of recurrence was 10.7%; with recurrence rates of 23.5% for the fertility preserving surgery population and 5.1% for the definitive surgery population. Ultrasound first identified 5 of the 6 (83.3%) recurrences. Overall time to recurrence was 51.5 months. In conclusion, recurrences were identified on routine ultrasound screening prior to symptom onset or detection via physical exam in 83.3% of cases. While the best modality of follow-up remains controversial, this review provides evidence supporting the use of routine ultrasound follow-up for early detection of BOT recurrence.<\/jats:p>","DOI":"10.3390\/cancers15010073","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T03:26:25Z","timestamp":1671765985000},"page":"73","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Identifying Borderline Ovarian Tumor Recurrence Using Routine Ultrasound Follow-Up"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4856-3553","authenticated-orcid":false,"given":"Caitlin","family":"Lazurko","sequence":"first","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomer","family":"Feigenberg","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Trillium Health Partners, Credit Valley Hospital, Mississauga, ON L5M 2N1, Canada"},{"name":"Department of Obstetrics & Gynaecology, University of Toronto, Toronto, ON M5G 1E2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Murphy","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Trillium Health Partners, Credit Valley Hospital, Mississauga, ON L5M 2N1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Pulman","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Trillium Health Partners, Credit Valley Hospital, Mississauga, ON L5M 2N1, Canada"},{"name":"Department of Obstetrics & Gynaecology, University of Toronto, Toronto, ON M5G 1E2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevieve","family":"Lennox","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Trillium Health Partners, Credit Valley Hospital, Mississauga, ON L5M 2N1, Canada"},{"name":"Department of Obstetrics & Gynaecology, University of Toronto, Toronto, ON M5G 1E2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Dube","sequence":"additional","affiliation":[{"name":"Department of Pathology, Trillium Health Partners, Credit Valley Hospital, Mississauga, ON L5M 2N1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5365-2518","authenticated-orcid":false,"given":"Tiffany","family":"Zigras","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Trillium Health Partners, Credit Valley Hospital, Mississauga, ON L5M 2N1, Canada"},{"name":"Department of Obstetrics & Gynaecology, University of Toronto, Toronto, ON M5G 1E2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.mpdhp.2014.07.001","article-title":"Ovarian borderline tumours: A review with comparison of serous and mucinous types","volume":"20","author":"McCluggage","year":"2014","journal-title":"Diagn. Histopathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<278::AID-CNCR14>3.0.CO;2-T","article-title":"Ovarian Papillary Serous Tumors of Low Malignant Potential (Serous Borderline Tumors): A Long Term Follow-up Study, Including Patients with Microinvasion, Lymph Node Metastasis, and Transformation to Invasive Serous Carcinoma","volume":"78","author":"Kennedy","year":"1996","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1634\/theoncologist.2012-0139","article-title":"Diagnosis, Treatment, and Follow-Up of Borderline Ovarian Tumors","volume":"17","author":"Fischerova","year":"2012","journal-title":"Oncologist"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/IGC.0000000000000282","article-title":"Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Tumors of Low Malignant Potential (Borderline Ovarian Tumors)","volume":"24","author":"Harter","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ygyno.2008.12.034","article-title":"Surgical management of borderline ovarian tumors: The role of fertility-sparing surgery","volume":"113","author":"Park","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/gyno.2000.6099","article-title":"Ultrasound, Physical Examination, and CA 125 Measurement for the Detection of Recurrence after Conservative Surgery for Early Borderline Ovarian Tumors","volume":"81","author":"Zanetta","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"ref_7","first-page":"30","article-title":"Borderline Ovarian Tumor\u2014An Overview and Evidence Based Management","volume":"2","author":"Perween","year":"2019","journal-title":"Pan. Asian J. Obs. Gyn."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3332\/ecancer.2020.1031","article-title":"Borderline ovarian tumours: Management in the era of fertility-sparing surgery","volume":"14","author":"Maramai","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"ref_9","unstructured":"National Comprehensive Cancer Network (NCCN) (2021). Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer (Version 1.2021), NCCN."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.5468\/ogs.2015.58.2.98","article-title":"Clinicopathological aspects of patients with recurrence of borderline ovarian tumors","volume":"58","author":"Oh","year":"2015","journal-title":"Obstet. Gynecol. Sci."},{"key":"ref_11","first-page":"151","article-title":"Fertility and borderline ovarian tumor: A systematic review of conservative management, risk of recurrence and alternative options","volume":"19","author":"Fauvet","year":"2012","journal-title":"Hum. Reprod. Updat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ygyno.2010.11.016","article-title":"Risk factors for recurrence of ovarian borderline tumors","volume":"120","author":"Shih","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/01.pas.0000213294.81154.95","article-title":"The Recurrence and the Overall Survival Rates of Ovarian Serous Borderline Neoplasms With Noninvasive Implants is Time Dependent","volume":"30","author":"Silva","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1525-1438.1993.03060349.x","article-title":"DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary","volume":"3","author":"Kaern","year":"1993","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0015-0282(03)00160-2","article-title":"Safety of conservative management and fertility outcome in women with borderline tumors of the ovary","volume":"79","author":"Donnez","year":"2003","journal-title":"Fertil. Steril."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jcma.2011.04.003","article-title":"Unilateral salpingo-oophorectomy as fertility-sparing surgery for borderline ovarian tumors","volume":"74","author":"Tsai","year":"2011","journal-title":"J. Chin. Med Assoc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/1097-0142(19940815)74:4<1398::AID-CNCR2820740433>3.0.CO;2-J","article-title":"Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study","volume":"74","author":"Schutter","year":"1994","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/annonc\/mdq414","article-title":"How to follow up advanced-stage borderline tumours? Mode of diagnosis of recurrence in a large series stage II\u2013III serous borderline tumours of the ovary","volume":"22","author":"Uzan","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/sj.bjc.6605065","article-title":"Clinical management of borderline tumours of the ovary: Results of a multicentre survey of 323 clinics in Germany","volume":"100","author":"Coumbos","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2013","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/annonc\/mdu139","article-title":"Influence of histological subtypes on the risk of an invasive recurrence in a large series of stage I borderline ovarian tumor including 191 conservative treatments","volume":"25","author":"Uzan","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_22","first-page":"363","article-title":"Ultrasound bioeffects and safety","volume":"224","year":"2009","journal-title":"Proc. Inst. Mech. Eng. Part H: J. Eng. Med."},{"key":"ref_23","unstructured":"Advisory Group on Non-Ionising Radiation Health Effects of Exposure to Ultrasound and Infrasound (2022, June 01). Health Effects of Exposure to Ultrasound and Infrasound, Available online: .https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/335014\/RCE-14_for_web_with_security.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/8756479309336240","article-title":"Accuracy and Cost Comparison of Ultrasound Versus Alternative Imaging Modalities, Including CT, MR, PET, and Angiography","volume":"25","author":"Bierig","year":"2009","journal-title":"J. Diagn. Med Sonogr."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/1\/73\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:48:38Z","timestamp":1760147318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/1\/73"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cancers15010073"],"URL":"https:\/\/doi.org\/10.3390\/cancers15010073","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2022,12,22]]}}}